Nyxoah SA Logo

Nyxoah SA

Develops & commercializes implantable neurostimulation therapy for severe Obstructive Sleep Apnea.

NYXH | BR

Overview

Corporate Details

ISIN(s):
BE0974358906
LEI:
5493002O1ESKZ18OXR80
Country:
Belgium
Address:
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert
Sector:
Manufacturing
Industry:
Manufacture of irradiation, electromedical and electrotherapeutic equipment

Description

Nyxoah SA is a commercial-stage medical technology company focused on the development and commercialization of innovative solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, an implantable neurostimulation therapy designed to treat patients with moderate to severe OSA. The system works by providing bilateral stimulation to the hypoglossal nerve, which controls the tongue muscles, thereby keeping the airway open during sleep. It is intended as a therapeutic alternative for patients who cannot tolerate or have failed traditional Continuous Positive Airway Pressure (CPAP) therapy.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 22:40
Legal Proceedings Report
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
English 10.7 KB
2025-08-29 22:30
Declaration of Voting Results & Voting Rights Announcements
2025 08 29 - Press release - Number of shares (ENG).pdf
English 522.4 KB
2025-08-29 22:30
Declaration of Voting Results & Voting Rights Announcements
2025 08 29 - Press release - Number of shares (FR).pdf
French 521.0 KB
2025-08-18 22:10
Earnings Release
ENGLISH_Q2 2025 Earnings PR_FINAL.pdf
English 316.1 KB
2025-08-18 22:10
Earnings Release
FRENCH_Q2 2025 Earnings PR_FINAL.pdf
French 310.1 KB
2025-08-18 22:10
Interim Report
Q2 2025 financial report (Euronext) (ENG) (final).pdf
English 800.2 KB
2025-08-18 22:10
Interim Report
Q2 2025 financial report (Euronext) (FR) (final).pdf
French 803.6 KB
2025-08-18 22:10
Earnings Release
Nyxoah Reports Second Quarter Financial and Operating Results
English 55.6 KB
2025-08-11 07:00
Earnings Release
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
English 14.8 KB
2025-08-08 23:30
Regulatory News Service
Nyxoah Receives Approval from FDA for Genio System for the Treatment of Obstruc…
English 12.9 KB
2025-08-08 22:10
Regulatory News Service
ENGLISH_FDA APPROVAL PRESS RELEASE - FINAL.pdf
English 156.0 KB
2025-08-08 22:10
Regulatory News Service
FRENCH_FDA APPROVAL PRESS RELEASE - FINAL.pdf
French 166.1 KB
2025-07-29 22:45
Declaration of Voting Results & Voting Rights Announcements
2025 07 29 - Press release - Number of shares (ENG).pdf
English 136.6 KB
2025-07-29 22:45
Declaration of Voting Results & Voting Rights Announcements
2025 07 29 - Press release - Number of shares (FR).pdf
French 136.0 KB
2025-07-28 22:05
Legal Proceedings Report
Nyxoahs DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Med…
English 14.7 KB

Automate Your Workflow. Get a real-time feed of all Nyxoah SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Nyxoah SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-19 Laurette Renard Close relation Sell 5,000 39,000.00 EUR
2024-09-05 Hambrecht Jürgen Board Sell 980,000 6,840,400.00 EUR
2024-09-05 JH Capital GmbH Close relation Buy 980,000 6,840,400.00 EUR
2024-01-25 Tompkins Patrick Executive member Buy 2,000 18,020.00 USD
2023-12-28 Onkelinx Bruno Executive member Buy 470 2,035.10 EUR
2023-08-18 Moreau Loïc Executive member Buy 6,427 48,416.52 EUR
2023-08-14 Moreau Loïc Executive member Buy 3,800 28,697.60 EUR
2023-08-11 Moreau Loïc Executive member Buy 3,000 21,957.60 EUR
2023-07-04 Wildman Ventures LLC Board Buy 25,000 N/A
2023-07-02 Gianello Pierre Board Buy 25,000 N/A

Peer Companies

Company Country Ticker View
Acarix Logo
AI-powered acoustic system for rapid, non-invasive rule-out of Coronary Artery Disease.
Sweden ACARIX
Develops a pain-free breath device to measure blood glucose for diabetes management.
Poland AME
Arcoma AB Logo
Develops and manufactures advanced digital X-ray and radiology solutions for global healthcare.
Sweden ARCOMA
ASTERASYS Co., Ltd. Logo
Develops HIFU and body analysis devices for the global aesthetic and healthcare market.
South Korea 450950
BIO PROTECH INC. Logo
Manufactures medical devices and consumables for surgery, cardiology, neurology & pain management.
South Korea 199290
Bistos Co., Ltd. Logo
Global maker of biosignal devices for patient monitoring, maternal-fetal, and neonatal care.
South Korea 419540
Develops software & hardware for precise surgical navigation and radiation therapy.
Germany N/A
Brainsway Ltd. Logo
Develops noninvasive Deep TMS therapy for depression, OCD, and smoking cessation.
Israel BWAY
AI-powered smart insoles providing gait analysis for neurological condition monitoring.
South Korea 352770
Chordate Medical Holding AB Logo
Develops drug-free neuromodulation tech for chronic migraine & rhinitis in the EU & Middle East.
Sweden CMH

Talk to a Data Expert

Have a question? We'll get back to you promptly.